Mydrate
Rx10 mg/ml • Ophthalmic Solution
ইঙ্গিত ও ব্যবহার
Mydrate ophthalmic solution is used chiefly to bring about mydriasis and cycloplegia for diagnostic eye examinations.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Adults and children over 1 year, for producing mydriasis and cycloplegia before eye examinations: instil 1 drop in the eye(s), with a second drop after 5 minutes if needed. Drops should be given 40 to 50 minutes before the procedure. To reduce absorption into the body, press a finger against the tear duct (inner corner of the eye) for 2 to 3 minutes after each drop, or alternatively, keep the eyelids closed for 2 to 5 minutes. People with darker (heavily pigmented) irises may need higher doses. Vision should return to normal, with mydriasis and cycloplegia fully resolved, within 24 hours. Use in children: Infants, young children, and children with fair hair or blue eyes may be more sensitive to cyclopentolate's effects, raising their risk of side effects during treatment. Its use in children has been linked to psychotic reactions and behavioural disturbances.
পার্শ্বপ্রতিক্রিয়া
Blinding acute angle-closure glaucoma and raised intraocular pressure may occur during cyclopentolate therapy. The mydriasis may be reduced by the intraocular application of pilocarpine, physostigmine or isoflurophate. A transient burning sensation of the eye is more likely with the 0.5% solution. Systemic effects, resulting from excessive absorption from mucosal surfaces or from ingestion of the drug, may include xerostomia, flushing, tachycardia and urinary retention. More severe systemic effects include tachypnea, scarlatiniform rash, delirium, psychosis, fever, stupor, coma, respiratory failure and death.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Mydrate may cause increased intraocular pressure. In patients with a higher susceptibility to raised intraocular pressure, including the elderly and those with shallow anterior chambers, cyclopentolate may induce angle-closure glaucoma. If this rise in pressure is sustained, it can potentially lead to irreversible loss of vision. Mydrate should be discontinued and a physician consulted immediately if eye pain, blurred vision, a rapid pulse or dizziness occurs. Because mydriasis is accompanied by photophobia, patients may need to wear dark glasses after Mydrate is applied. Patients should also be advised to contact their physician if blurred vision and photophobia continue for more than 48 hours after stopping cyclopentolate. Topical cyclopentolate can be absorbed systemically through the nasal mucosa, which may result in systemic adverse effects; children are especially susceptible to this. If signs of systemic toxicity appear, such as dry mouth, a rapid heartbeat or dizziness, the dosage schedule should be reduced or the drug discontinued.
নিষেধাজ্ঞা
Cyclopentolate should not be used in people with angle-closure glaucoma or shallow anterior chambers. It should also be avoided by anyone, especially children, who has previously had a severe systemic reaction to the drug, and by anyone hypersensitive to any component of a cyclopentolate formulation.